Sen­ate health com­mit­tee ad­vances changes to how FDA would ap­prove new opi­oids

The Sen­ate Health, Ed­u­ca­tion, La­bor and Pen­sions com­mit­tee on Tues­day af­ter­noon ad­vanced three ma­jor bills re­lat­ed to the opi­oid epi­dem­ic and can­cer screen­ing, in­clud­ing an amend­ment that would trans­form how the FDA reg­u­lates opi­oids.

In­sert­ed in­to the reau­tho­riza­tion of the Sup­port Act, which aims to take the opi­oid cri­sis head-on with more funds and re­sources, Sen. Mike Braun’s (R-IN) amend­ment would al­low the FDA to con­sid­er whether each new opi­oid ap­proved “pro­vides a sub­stan­tial im­prove­ment, in terms of greater safe­ty or greater ef­fec­tive­ness, or ma­jor con­tri­bu­tion to pa­tient care” when com­pared to cur­rent­ly ap­proved opi­oids.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER